Our Companies

Jefferson has a long history of developing ideas into companies, and commercializing breakthrough technologies. Here are just a few of our successes that started right here at Jefferson.

Sillajen

Phase 3 trial in progress in advanced liver cancer patients, using Pexa-Vec in combination with Sutent (sorafenib), expected to conclude in 2018. In advanced colorectal cancer, Sillajen in August 2017 announced a partnership with the National Cancer Institute to initiate clinical trials of Pexa-Vec in combination other checkpoint inhibitors.

Clementia

Successful Phase 2 double-blind trial of Palvarotene for FOP reported in October 2016. Phase III multi-center, open label, pivotal trial in design phase. Pipeline includes use of Palvarotene for Multiple Osteochondromas (MO) and for Dry Eye Disease. 

Targeted Diagnostics & Therapeutics (TDT)

Successful Phase I clinical trial completed in 2015, showing safety, tolerability, and immunological efcacy in stage 1 and stage 2 colon cancer patients. Phase II trial planning and Orphan Drug Status Application underway in partnership with Viral Gene Inc. 

Imvax

Antisense molecule targeted to glioblastomas (brain cancers) now enrolling patients in Phase 1b trial.   

Circalux

Founded as a C-corp in June 2016 after completion of JefDESIGN program. Consumer product launching via Kickstarter campaign. Planning for tests to assist in nocturnal patient care. 

Conatus

Strong preclinical study results. DN-7314 granted Orphan Drug Designation for the treatment of primary sclerosing cholangitis (PSC) on 6/27/17. 

Immunome

Series A funded in 2016 and 2017 tranches, to further develop therapeutics based on antigen-antibody pairs, using antibodies from patients raised against their own tumors. Developed by TJU and MIT Whitehead Institute. 

NuView

Initial product in development is in vitro prostate cancer urine screen using NuView VPAC1 molecular imaging agent. Pipeline includes in vivo breast and prostate imaging agents. Subsidiary US Radiopharmaceuticals is 85,000 sq ft FDA-registered, cGMP medical isotope manufacturing and distribution facilities. 

Capillary Biomedical

Preclinical animal studies in progress. Research funded by Juvenile Diabetes Research Association. TJU students won frst prize at 2016 Diabetes Technology Meeting. 

Akriveia Therapeutics

Phase 3 trial in progress in advanced liver cancer patients, using Pexa-Vec in combination with Sutent (sorafenib), expected to conclude in 2018. In advanced colorectal cancer, Sillajen in August 2017 announced a partnership with the National Cancer Institute to initiate clinical trials of Pexa-Vec in combination other checkpoint inhibitors.